Company intelligence / Profile preview
MBX Biosciences, Inc.
Carmel, Indiana, United Statesmbxbio.com ↗
- Ownership
- Public · MBX
- Development stage
- Other
01
Overview
Enrollment complete in Phase 2 Avail™ trial of canvuparatide in hypoparathyroidism with topline results expected in Q3 2025. MBX 1416 completed Phase 1 trials with Phase 2 for post-bariatric hypoglycemia expected to begin in 2H 2025. IND submission for MBX 4291 in obesity anticipated in Q2 2025.[4][9]
- Therapeutic areas
- EndocrinologyMetabolic Disorders
- Modalities
- Precision peptide therapiesPeptide prodrugs
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
03
Financials
- Market cap
- $2.3B
- Total revenue
- $0
- Enterprise value
- $1.9B
Beyond the preview
Go deeper on MBX Biosciences, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MBX Biosciences, Inc..